Search tickers (stock/ETF/mutual fund)...
  • Screener
  • Watchlist
  • Charts
  • Gurus
  • Copilot
    Filings Search  
    Plans   
    Login   
    Register   
    Backtest Portfolio
    Portfolio Optimization
    Asset Correlations
    Efficient Frontier

    KNE.V Gross Margin

    As of 2025-07-16, the Gross Margin of Kane Biotech Inc (KNE.V) is 41.9%.

    Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.

    KNE.V Gross Margin - Historical Value
    DateValue
    2024-12-31 41.9%
    2023-12-31 73.5%
    2022-12-31 53%
    2021-12-31 35.4%
    2020-12-31 39.3%
    2019-12-31 36%
    2018-12-31 15.4%
    2017-12-31 -20%
    2016-12-31 49.2%
    2015-12-31 57%
    KNE.V Gross Margin - Peers Comparison
    TickerNameValue
    ADYXAdynxx Inc22.4%
    AMBSAmarantus Bioscience Holdings Inc7775.2%
    ANTHAnthera Pharmaceuticals Inc7775.2%
    APC.VAdvanced Proteome Therapeutics Corporation39.7%
    BIEIPremier Graphene Inc9.9%
    BIXTBioxytran Inc45.6%
    BZYRBurzynski Research Institute Inc7775.2%
    CAPSCapstone Holding Corp84.8%
    CBBTCerebain Biotech Corp-
    HEM.VHemostemix Inc7775.2%
    HXBMHelix BioMedix Inc36.8%
    ICO.ViCo Therapeutics Inc-
    IMMBImmunotech Laboratories Inc7775.2%
    IMUCEom Pharmaceutical Holdings Inc7775.2%
    MRPIMera Pharmaceuticals Inc94.6%
    NOHONovation Holdings Inc76.9%
    NSTMNovelstem International Corp13.9%
    OBMPTheralink Technologies Inc71%
    PAS.VPascal Biosciences Inc7775.2%
    PFNDPathfinder Cell Therapy Inc31.5%
    TXTMProtext Mobility Inc100%
    VGLSVG Life Sciences Inc7775.2%
    VXL.VVaxil Bio Ltd7775.2%
    WAVE.VWaverley Pharma Inc45%
    XBIOXenetic Biosciences Inc97.9%
    XSNXNovAccess Global Inc34%
    Tickers added to watchlist